CRISPR Therapeutics, Vertex Up After CTX001 Gets RMAT Designation
May 11 2020 - 12:49PM
Dow Jones News
By Michael Dabaie
CRISPR Therapeutics shares were up 12% to $60.41 in midday
trading.
CRISPR and Vertex Pharmaceuticals Inc. said the U.S. Food and
Drug Administration granted Regenerative Medicine Advanced Therapy
designation to CTX001 for the treatment of severe sickle cell
disease and transfusion-dependent beta thalassemia.
Vertex shares were up 4% to $282.04.
CTX001 is being developed under a co-development and
co-commercialization agreement between CRISPR Therapeutics and
Vertex.
RMAT designation is a dedicated program designed to expedite the
drug development and review processes for promising pipeline
products, including genetic therapies.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 11, 2020 12:34 ET (16:34 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Mar 2024 to Apr 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Apr 2023 to Apr 2024
